MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

Blood

Volumn 114, Issue 16, 2009, Pages 3448-3458

  Figueroa, Maria E ^a   Skrabanek, Lucy ^a   Li, Yushan ^a   Jiemjit, Anchalee ^b   Fandy, Tamer E ^b   Paietta, Elisabeth ^c   Fernandez, Hugo ^d   Tallman, Martin S ^e   Greally, John M ^f   Carraway, Hetty ^b   Licht, Jonathan D ^e   Gore, Steven D ^b   Melnick, Ari ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; ENTINOSTAT; GENOMIC DNA; HISTONE DEACETYLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; WNT PROTEIN; CD34 ANTIGEN; DNA; ENZYME INHIBITOR; HISTONE DEACETYLASE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; BONE MARROW CELL; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA METHYLATION; HUMAN; HUMAN CELL; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; MALE; METABOLISM; SECOND CANCER; TIME;

ANTIGENS, CD34; AZACITIDINE; BONE MARROW CELLS; DNA METHYLATION; DNA, NEOPLASM; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MAP KINASE SIGNALING SYSTEM; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PROMOTER REGIONS, GENETIC; TIME FACTORS; WNT PROTEINS;

EID: 70350720044     PISSN: 00064971     EISSN: 15280020     Source Type: None    
DOI: 10.1182/blood-2009-01-200519     Document Type: Article

References (39)

1. Plass C. Cancer epigenomics. Hum Mol Genet. 2002;11(20):2479-2488.
2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042-2054. (Pubitemid 37448928)
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415-428.
4. Tessema M, Langer F, Dingemann J, Ganser A, Kreipe H, Lehmann U. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia. 2003;17(5):910-918. (Pubitemid 36626319)
5. Brakensiek K, Langer F, Schlegelberger B, Kreipe H, Lehmann U. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol. 2005;130(2):209-217. (Pubitemid 41602521)
6. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2003;17(9):1813-1819. (Pubitemid 37185257)
7. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol. 2006;76(1):23-32.
8. Griffiths E, Gore S. DNA Methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes Semin Hematol. 2008;45(1):23-30.
9. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20(10):2429-2440. (Pubitemid 34525728)
10. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(24):3895- 3903.
11. Fenaux P. Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nat Clin Pract Oncol. 2005;2(suppl 1):S36-S44. (Pubitemid 43135233)
12. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
13. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113(6):1315-1325.
14. Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 2007;21(9):1937-1944. (Pubitemid 47299967)
15. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66(12):6361-6369.
16. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52-57. (Pubitemid 46053042)
17. Karpf AR, Moore BC, Ririe TO, Jones DA. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-Aza-2′-deoxycytidine. Mol Pharmacol. 2001; 59(4):751-757.
18. Zhu W-G, Hileman T, Ke Y, et al. 5-Aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem. 2004; 279(15):15161-15166.
19. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008;28(2):752-771.
20. Kuo HK, Griffith JD, Kreuzer KN. 5-Azacytidine induced methyltransferase-DNA adducts block DNA replication in vivo. Cancer Res. 2007;67(17):8248-8254.
21. Khulan B, Thompson R, Ye K, et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res. 2006;16(8):1046-1055. (Pubitemid 44162264)
22. Figueroa ME, Reimers M, Thompson RF, et al. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One. 2008;3(3):e1882. (Pubitemid 351943731)
23. Selzer RR, Richmond TA, Pofahl NJ, et al. Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer. 2005;44(3):305-319.
24. Thompson RF, Reimers M, Khulan B, et al. An analytical pipeline for genomic representations used for cytosine methylation studies. Bioinformatics. 2008;24(9):1161-1167. (Pubitemid 351594165)
25. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207-210.
26. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A. 2005;102(44):15785-15790. (Pubitemid 41552820)
27. R: A Language and Environment for Statistical Computing [computer program]. Version 2.8. Vienna: R Foundation for Statistical Computing; 2008.
28. Gentleman R, Carey V, Bates D, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80. (Pubitemid 44291424)
29. Culhane AC, Thioulouse J, Perriere G, Higgins DG. MADE4: an R package for multivariate analysis of gene expression data. Bioinformatics. 2005;21(11):2789-2790. (Pubitemid 40852331)
30. Smit A, Hubley R, Green P. RepeatMasker Open- 3.0. 1996-2004. http://www.repeatmasker.org. Accessed July 2009.
31. Elemento O, Slonim N, Tavazoie S. A universal framework for regulatory element discovery across all genomes and data types. Mol Cell. 2007;28(2):337-350. (Pubitemid 47600005)
32. Karolchik D, Kuhn RM, Baertsch R, et al. The UCSC Genome Browser Database: 2008 update. Nucleic Acids Res. 2008;36(Database issue): D773-D779.
33. Polak P, Domany E. Alu elements contain many binding sites for transcription factors and may play a role in regulation of developmental processes. BMC Genomics. 2006;7:133. (Pubitemid 44110475)
34. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I trial of the epigenetic modulators Vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study of the New York Cancer Consortium [abstract]. Blood. 2008;112(11):Abstract 3656.
35. Fandy TE, Herman JG, Kerns K, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009;114(13):2764-2773.
36. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther. 2008;7(9):2998-3005.
37. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med. 2004. 2004;10(5):481-483.
38. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat Genet. 1999;21(1):103-107. (Pubitemid 29036293)
39. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F. Characterization of DNA demethylation effects induced by 5-Aza-2′-Deoxycytidine in patients with myelodysplastic syndrome. Cancer Res. 2005;65(16):7086-7090. (Pubitemid 41161236)